Conversely, in Type 2, after a peak around the index date, there is a decreasing trend in MHC use associated with other diagnoses alongside the autism diagnosis, except for SSD (affecting 60% of individuals).
1
—
—
Conversely, in Type 2, after a peak around the index date, there is a decreasing trend in MHC use associated with other diagnoses alongside the autism diagnosis, except for SSD (affecting 60% of individuals).